ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

BHVN Company Profile and Key Details

NYSE : BHVN

Biohaven Pharmaceutical Holding Company Ltd.

$18.59

-1.96-9.54%

At Close 4:00 PM

69.44

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

BHVN Stock Price Chart

Stock Price Today

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock declined over -9.54%, trading at $18.59 on NYSE, down from the previous close of $20.55. The stock opened at $19.47, fluctuating between $17.93 and $19.92 in the recent session.

Stock Snapshot

20.55

Prev. Close

19.47

Open

1.9B

Market Cap

102.07M

Number of Shares

17.93

Day Low

19.92

Day High

-2

P/E Ratio

85.55%

Free Float in %

-9.28

EPS (TTM)

5.35

Book Value

-4.19

Cash Flow per Share

2.58M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 04, 2025	19.47	19.92	17.93	18.59	2.58M
Apr 03, 2025	21.95	22.24	20.41	20.55	2.68M
Apr 02, 2025	22.34	24.09	21.89	23.69	939.53K
Apr 01, 2025	24.10	24.21	21.68	22.60	2.09M
Mar 31, 2025	26.48	26.48	21.47	24.04	3.52M
Mar 28, 2025	28.25	28.50	26.57	27.65	1.09M
Mar 27, 2025	29.00	29.62	28.28	28.39	603.6K
Mar 26, 2025	29.86	30.21	28.22	28.86	821.25K
Mar 25, 2025	30.89	31.18	29.65	29.87	894.7K
Mar 24, 2025	28.99	31.08	28.78	31.04	1.07M
Mar 21, 2025	27.76	28.88	27.21	28.54	1.09M
Mar 20, 2025	28.25	28.75	27.91	28.17	814.93K
Mar 19, 2025	28.73	29.26	28.30	28.75	577.4K
Mar 18, 2025	29.38	29.61	28.66	28.85	506.84K
Mar 17, 2025	29.13	29.83	28.38	29.66	738.54K
Mar 14, 2025	28.76	29.65	28.50	29.15	653.84K
Mar 13, 2025	29.25	29.73	27.94	28.22	717.65K
Mar 12, 2025	29.92	30.35	28.90	29.41	909.29K
Mar 11, 2025	27.40	29.62	26.96	29.41	1.99M
Mar 10, 2025	28.62	29.47	27.40	27.63	1.9M

Contact Details

New Haven, CT 06510

United States

Website: https://www.biohavenpharma.comContact: 203 404 0410

About Company

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Frequently Asked Questions

What is the current Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock price?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock price is $18.59 in the last trading session. During the trading session, BHVN stock reached the peak price of $19.92 while $17.93 was the lowest point it dropped to. The percentage change in BHVN stock occurred in the recent session was -9.54% while the dollar amount for the price change in BHVN stock was -$1.96.

BHVN's industry and sector of operation?

The NYSE listed BHVN is part of Biotechnology industry that operates in the broader Healthcare sector. Biohaven Pharmaceutical Holding Company Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BHVN?

Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Mr. John Tilton
Chief Commercial Officer of Rare Diseases
Mr. Matthew Buten
Chief Financial Officer
Mr. George C. Clark
Vice President & Chief Accounting Officer
Mr. Chris Barrett
Senior Vice President of Commercial Strategy, Common Disease
Mr. Warren Volles
Gen. Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.
Chief Compliance Officer
Mr. Warren Volles J.D.
Gen. Counsel & Chief Legal Officer
Ms. Deb Young
Director of Regulatory Affairs & Operations
Ms. Jennifer Porcelli
Head of Investor Relations
Dr. Bruce D. Car DACVP, Ph.D.
Consultant
Dr. Vladimir Coric M.D.
Chairman & Chief Executive Officer

How BHVN did perform over past 52-week?

BHVN's closing price is 3.68% higher than its 52-week low of $17.93 where as its distance from 52-week high of $55.70 is -66.62%.

How many employees does BHVN have?

Number of BHVN employees currently stands at 256.

Link for BHVN official website?

Official Website of BHVN is: https://www.biohavenpharma.com

How do I contact BHVN?

BHVN could be contacted at phone 203 404 0410 and can also be accessed through its website. BHVN operates from 215 Church Street, New Haven, CT 06510, United States.

How many shares of BHVN are traded daily?

BHVN stock volume for the day was 2.58M shares. The average number of BHVN shares traded daily for last 3 months was 1.09M.

What is the market cap of BHVN currently?

The market value of BHVN currently stands at $1.90B with its latest stock price at $18.59 and 102.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	256
Beta	3.91
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology